Constellation Alpha Capital Corp

Constellation Alpha Capital — DermTech — Investor Presentation (December 2020)

32 slides from Constellation Alpha Capital's investor presentation, Dec 11, 2020

  1. Slide 1: Corporate Presentation Q4 2020

    Corporate Presentation Q4 2020 COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “an

  3. Slide 3: Leadership Team

    Leadership Team Founder & Chairman, 10xBio (aesthetic medicine drugs) Chairman, Pantherics (anti-inflammatory drugs) MD, UCSD, Bachelors, UCLA Allergan, VP US Sales, Dermatology, Ophthalmology, Aesthetics Dexcom, VP Finance, Corporate Controller and Treasury, Interim CFO Biosite, FP&A, SEC Reporting

  4. Slide 4: DermTech is a leader in precision dermatology

    DermTech, Inc. (NASDAQ: DMTK) is a leader in precision dermatology enabled by a non-invasive skin genomics platform We address large market opportunities in skin disease with an initial focus in skin cancer We operate a CLIA-certified and CAP-accredited commercial laboratory in San Diego, CA. Our sk

  5. Slide 5: Genomic Innovations Are Less Invasive, More Accurate, and Less Expensive

    Genomic Innovations Are Less Invasive, More Accurate, and Less Expensive Focus Company Old Standard of Care New-gen Diagnostic Breast Colorectal Thyroid Heart Lung Prenatal Skin COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

  6. Slide 6: PLA Brings Skin Cancer Diagnostics into the 21st Century

    PLA Brings Skin Cancer Diagnostics into the 21st Century A Better Diagnostic Solution for Dermatology Subjective Visual Assessment Surgical Biopsy Subjective Histopathology Adhesive Patch Sample Collection Genomic Analysis CLIA/CAP Commercial Lab Physician Report (within 72 hrs.) Subjective Low Accu

  7. Slide 7: A Snapshot of the U.S. Skin Cancer Market

    More people are diagnosed with skin cancer than all other cancers combined and 1 in 5 Americans will develop skin cancer by the age of 70. More than 50 MM patients have UV related skin damage that puts them at risk for skin cancer Annual cost of treatment is estimated to be $8.1 billion, $4.8 billio

  8. Slide 8: DermTech's Skin Cancer Product Pipeline

    DERMTECH’s Skin Cancer Product Pipeline Pigmented Lesion Assay (PLA) Melanoma R/O PLAplus Next Gen Melanoma R/O (Launch Postponed due to COVID Related Supply Chain Impacts) LuminateSM UV Damage and Skin Cancer Risk Carcinome Basal & Squamous Cell R/O CTCL Cutaneous T-cell Lymphoma R/O Product Discov

  9. Slide 9: Skin Cancer Market Opportunity

    PLA/PLAplusSM: melanoma1 skin cancer 4-4.5 MM diagnostic surgical biopsies Carcinome: non-melanoma skin cancer1 11-12 MM diagnostic surgical biopsies LuminateSM: UV damage and skin cancer risk2 82 MM U.S. Adults aged 35-54, ~1/3 actinic sun damage CTCL: Cutaneous lymphoma3 Estimated biopsies for inf

  10. Slide 10: Early Detection of Melanoma Is Critical to Survival

    When Diagnosed at the Local Stage When Diagnosed at the Regional Stage When Diagnosed at the Distant Stage Not Skin Cancer Skin Cancer Not Skin Cancer Skin Cancer Early Detection of Melanoma Is Critical to Survival 5-Year Relative Survival Rate1 Early Detection Visually Is Extremely Difficult 98% 64

  11. Slide 11: Unmet Need: Melanoma's Challenging Diagnostic Pathway

    ~4.0-4.5 million biopsies annually to identify 180k cases Subjective Clinical Visual Assessment Most Biopsies Are NOT Melanoma Unmet Need: Melanoma’s Challenging Diagnostic Pathway Multiple biopsies and excisions of benign pigmented lesions. Courtesy of G. Peck, MD. 1. Anderson A, et al., JAMA Derma

  12. Slide 12: The First Non-invasive Gene Expression and Mutation Test to Enhance Melanoma Detection

    The First Non-invasive Gene Expression and Mutation Test to Enhance Melanoma Detection COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. 1. Data on File. DermTech, Inc. 2. Jackson RJ, Jansen B, Yao Z, Ferris LK. Skin. 2020;4(2):105-110 3. Gerami P, Yao Z, Polsky D, et al. J Am Acad Dermatol. 2017;76(1

  13. Slide 13: Better Care at a Lower Cost

    Better Care at a Lower Cost Performance Metric Biopsy & Histology PLA Test Improvement Probability of Missed Melanoma1 17% 1% 17x Biopsies per Melanoma2 25 2.7 10x Wide Excisions per Melanoma2,3 5.2 1.6 3x Cost per Lesion Tested4 ~$1,000 $760 $240 Fewer biopsies while missing fewer melanomas A long-

  14. Slide 14: Strong Clinical Validation and Robust IP Portfolio

    Strong Clinical Validation and Robust IP Portfolio Milestone Status Sample Size Analytical Validation ✔ Complete 125 Clinical Validation – pathology ✔ Complete 555 Clinical Validation – mutation ✔ Complete 626 Clinical Utility ✔ Complete 45 Derms Real-World Utility ✔ Complete 381 1-Year Follow-up ✔

  15. Slide 15: CMS Pricing in Place Unlocks Significant Market Opportunity

    CMS Pricing in Place Unlocks Significant Market Opportunity ~2.0 Million Total Biopsies2 ~$1.5 Billion $760 Reimbursement2 ~2.0 Million Total Biopsies Reimbursement TBD Expect in-line with Medicare payment rate +$1 Billion (est.) Medicare Other Medicare Market Alone Has Potential for >$1 Billion in

  16. Slide 16: DermTech's Goal: Eliminate Melanoma Deaths in the US

    DermTech’s Goal: Eliminate Melanoma Deaths in the US There are 5 Requirements to Eradicate a Disease Diagnostic test with 99% NPV & is agreeable with patients Treatment protocol with 99% efficacy Payer model to fund effective diagnosis & treatment Widespread HCP adoption of diagnostic pathway & trea

  17. Slide 17: PLA Case Study – JAMA Dermatology Publication

    PLA Case Study – JAMA Dermatology Publication 28-year-old female Family history of melanoma Complained of bug bite Refused surgical biopsy PLA test was positive Histopathology revealed 0.5-mm melanoma Curative wide excision performed Case study published in JAMA Dermatology1 Effectiveness Attributes

  18. Slide 18: Commercial Activities

    Commercial Activities COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

  19. Slide 19: Commercial Channels

    Commercial Channels Telemedicine Integrated Primary Care Networks On- and near-site employer health clinics & retail clinics Social Media Paid Search Programmatic Display Direct sales reps Inside sales reps Regional managers Medical science liaisons Dermatology Professional Channel Digital Consumer

  20. Slide 20: Dermatology Professional Sales Force

    Dermatology Professional Sales Force Each circle represents a prioritized dermatology target: high number melanoma biopsies, >50% proportion Medicare patients 45-50 sales reps give coverage of 13,000 dermatology clinical professionals ~80% sales manger hiring complete ~5,000 prioritized targets Aver

  21. Slide 21: Digital Consumer Channel is Driving Awareness and Patients to Take Action

    Digital Consumer Channel is Driving Awareness and Patients to Take Action Source: Socialbakers; Google Analytics​; Acuity, May-Oct, 2020, select U.S. regions Data: Includes metrics across both published (organic and boosted) and unpublished content on owned social platforms​ The DermTech PLA | Early

  22. Slide 22: Future Cancer Care Dx Delivered via Telemedicine Channel

    Store & Forward iPhone and Android App Secure email and text HCP network of users Remote interactive access Sent to patient’s home Supported by easy to use instructions QR Code activates instructional video Employer service providers Benefit providers Integrated networks Other Telemedicine channels

  23. Slide 23: Ordering Clinician Installed Base and Sample Volume Resumed Growth Post Q2 COVID Shutdown

    Ordering Clinician Installed Based and Sample Volume Resumed Growth Post Q2 COVID Shutdown Trained Sales Reps: ~7 Trained Sales Reps: ~23 Trained Sales Reps: ~7 Trained Sales Reps: ~7 Trained Sales Reps: ~23 Trained Sales Reps: ~33 COVID-19 QTR Source: DermTech, Inc. Training program for new sales r

  24. Slide 24: Beginning to Monetize Sample Volume With Recent Medicare Coverage

    Beginning to Monetize Sample Volume With Recent Medicare Coverage DermTech Historical Quarterly Assay Revenue and ASP Trained Sales Reps: ~7 Trained Sales Reps: ~23 Trained Sales Reps: ~7 Trained Sales Reps: ~7 Trained Sales Reps: ~23 Trained Sales Reps: ~33 Source: DermTech, Inc., Capital IQ, Bloom

  25. Slide 25: Commercial Lab Operations

    Commercial Lab Operations CLIA-licensed laboratory in State of California and all states requiring out-of-state licensure CAP-accredited ~9000-square-foot commercial lab space Current floorspace capacity of 300,000 tests per year PLA/PLAplus assay turnaround time is ~3-4 days COPYRIGHT © 2020 DERMTE

  26. Slide 26: COVID-19 Impact Discussion

    Impact Discussion We are deemed an essential business and our commercial laboratory remains fully operational Dermatology offices have not yet re-opened to full capacity and future operations are dependent upon regional COVID-19 infection rates and regional restrictions We have been conducting virtu

  27. Slide 27: Back Up

    Back Up COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED.

  28. Slide 28: The PLAplus: Optimized Gene Targets

    THE PLAplus: Optimized Gene Targets Novel marker discovered by DermTech Member of a rapidly growing family of regulatory RNA molecules Important regulator of oncogenesis - play role in melanoma proliferation and invasion Overexpressed in melanoma Well described target involved in many tumors, includ

  29. Slide 29: Luminate: Quantifies UV Damage to the Genome

    Quantifies UV damage to the genome in normal appearing skin by assessing driver mutations for basal cell and squamous cell cancer Identifies risk for skin cancer and premature photoaging Generates UV Damage score Non-sun exposed areas of skin from the buttocks have zero score Patients with a history

  30. Slide 30: Research Partnerships and Collaborations

    ~$12 million in research programs booked to date Robust pipeline of opportunities and pending contracts Independent performance development Expansion to late-stage trials (phase ll, lll) Research Partnerships and Collaborations Indication* Pilot Phase 1 Phase 2 Phase 3 Pemphigus Vulgaris Hidradeniti

  31. Slide 31: Improved Practice Efficiency & Patient Capacity

    Improved Practice Efficiency & Patient Capacity Ambiguous lesions photographed & followed-up Most atypical/obvious lesion Patient with Multiple Pigmented Lesions Physician Billing Higher E&M Coding 1 Surgical Biopsy PLA Define PLA Positioning and Clarify Practice Economics The PLA Provides Comparabl

  32. Slide 32: Precision Dermatology Delivers More Accurate Melanoma Detection

    Precision Dermatology Delivers More Accurate Melanoma Detection Samples 100% of lesion Provides additional objective genomic information Measures malignant changes that cannot be seen visually Samples less than 1%-2% of a potentially partial surgical biopsy Relies on subjective visual criteria Morph

DermTech — Investor Presentation (December 2020) on 6ix